Patents Assigned to Mitotix, Inc.
-
Patent number: 6251585Abstract: The present invention makes available assays and reagents for identifying anti-proliferative agents, such as mitotic and meiotic inhibitors. The present assay provides a simple and rapid screening test which relies on scoring for positive cellular proliferation as indicative of anti-mitotic or anti-meiotic activity, and comprises contacting a candidate agent with a cell which has an impaired cell-cycle checkpoint and measuring the level of proliferation in the presence and absence of the agent. The checkpoint impairment is such that it either causes premature progression of the cell through at least a portion of a cell-cycle or inhibition of normal progression of the cell through at least a portion of a cell-cycle, but can be off-set by the action of an agent which inhibits at least one regulatory protein of the cell-cycle in a manner which counter-balances the effect of the impairment.Type: GrantFiled: April 24, 1995Date of Patent: June 26, 2001Assignee: Mitotix, Inc.Inventors: Giulio Draetta, Guillaume Cottarel, Veronique Damagnez
-
Patent number: 6146842Abstract: A high throughput enzyme screen has been developed which relies on metal chelate interaction for capture of the product of the enzymatic reaction. In the present assay system, a detectable moiety is attached to a substrate having a chelating capturable moiety, which can be captured by an immobilized metal. Detection is effected due to the presence of a detectable label on the reaction product immobilized on the solid phase. Only signal associated with tagged protein bound to the solid phase is detected. The present assay can reliably measure enzyme activity, and has high reproducibility, which benefits high throughput screening.Type: GrantFiled: September 17, 1999Date of Patent: November 14, 2000Assignee: Mitotix, Inc.Inventors: Serene Josiah, Michael Boisclair
-
Patent number: 6117641Abstract: The present invention relates to rapid, reliable and effective assays for screening and identifying pharmaceutically effective compounds that specifically inhibit the biological activity of fungal GTPase proteins, particularly GTPases involved in cell wall integrity, hyphael formation, and/or other cellular functions critical to pathogenesis.Type: GrantFiled: April 11, 1996Date of Patent: September 12, 2000Assignees: Mitotix, Inc., The John Hopkins UniversityInventors: Vivian Berlin, David E. Levin, Yoshikazu Ohya
-
Patent number: 6068982Abstract: The present invention relates to drug screening assays which provide a systematic and practical approach for the identification of candidate agents able to inhibit ubiquitin-mediated degradation of a cell-cycle regulatory protein, such as p53, p27, myc, fos, MAT.alpha.2, or cyclins. The invention further relates to novel ubiquitin-conjugating enzymes, and uses related thereto.Type: GrantFiled: December 17, 1996Date of Patent: May 30, 2000Assignee: Mitotix, Inc.Inventors: Mark Rolfe, Maria Isabel Chiu, Guillaume Cottarel, Vivian Berlin, Veronique Damagnez, Giulio Draetta
-
Patent number: 6060262Abstract: The present invention relates to drug screening assays which provide a systematic and practical approach for the identification of candidate agents able to inhibit ubiquitin-mediated degradation of I.kappa.B and other I.kappa.B-related polypeptides.Type: GrantFiled: July 16, 1997Date of Patent: May 9, 2000Assignee: Mitotix, Inc.Inventors: Peggy Beer-Romero, Peter J. Strack, Susan J. Glass, Mark Rolfe
-
Patent number: 6015692Abstract: The present invention relates to the discovery in mammalian cells, particularly human cells, of a novel CDK-binding protein, referred to herein as "cdc37". As described herein, this protein functions to facilitate activation and accordingly finctions in the modulation of cell-cycle progression, and therefore ultimately of cell growth and differentiation. Moreover, binding data indicated that cdc37 may function coordinately with other cell-cycle regulatory proteins, such as of cyclin-dependent kinases (CDKs), src, p53 and erk kinases.Type: GrantFiled: May 9, 1997Date of Patent: January 18, 2000Assignee: Mitotix, Inc.Inventors: Jeno Gyuris, Lou Lamphere, Giulio Draetta
-
Patent number: 5981699Abstract: The present invention concerns a novel human ubiquitin-conjugating enzyme which is implicated in the ubiquitin-mediated inactivation of cell-cycle regulatory proteins, partucularly p53. The present invention makes available diagnostic and therapeutic assays and reagents for detecting and treating transformed cells, such as may be useful in the detection of cancer. The present invention also provides reagents for altering the normal regulation cell proliferation in untransformed cells, such as by upregulating certain cell-cycle checkpoints, e.g. to protect normal cells against DNA damaging reagents.Type: GrantFiled: May 23, 1994Date of Patent: November 9, 1999Assignee: Mitotix, Inc.Inventors: Giulio Draetta, Mark Rolfe, Jens W. Eckstein
-
Patent number: 5968761Abstract: The present invention relates to drug screening assays which provide a systematic and practical approach for the identification of candidate agents able to inhibit ubiquitin-mediated degradation of a cell-cycle regulatory protein, such as p53, p27, myc, fos, MAT.alpha.2, or cyclins. The invention further relates to novel ubiquitin-conjugating enzymes, and uses related thereto.Type: GrantFiled: June 7, 1995Date of Patent: October 19, 1999Assignee: Mitotix, Inc.Inventors: Mark Rolfe, Maria Isabel Chiu, Guillaume Cottarel, Vivian Berlin, Veronique Damagnez, Giulio Draetta
-
Patent number: 5858987Abstract: The present invention relates to the discovery that antisense nucleic acids complimentary to an E6AP gene can be used to regulate cellular p53 levels. In general the invention features E6AP antisense constructs which, by inhibiting E6AP activity, can modulate cellular p53 levels in both p53+ transformed cells and in normal cells. The invention also provides methods for treating papillomavirus (PV) induced condition, methods for regulating cellular p53 levels and methods for regulating cellular proliferation.Type: GrantFiled: May 5, 1995Date of Patent: January 12, 1999Assignee: Mitotix, Inc.Inventors: Peggy L. Beer-Romero, Giulio Draetta, Mark Rolfe
-
Patent number: 5801015Abstract: The present invention relates to the discovery of novel cell cycle regulatory proteins from the human pathogen Candida.Type: GrantFiled: June 5, 1995Date of Patent: September 1, 1998Assignee: Mitotix, Inc.Inventors: Guillaume Cottarel, Veronique Damagnez, Giulio Draetta
-
Patent number: 5756671Abstract: The present invention relates to the discovery in mammalian cells, particularly human cells, of a novel CDK-binding protein, referred to herein as "cdc37". As described herein, this protein functions to facilitate activation and accordingly functions in the modulation of cell-cycle progression, and therefore ultimately of cell growth and differentiation. Moreover, binding data indicated that cdc37 may function coordinately with other cell-cycle regulatory proteins, such as of cyclin-dependent kinases (CDKs), src, p53 and erk kinases.Type: GrantFiled: April 1, 1996Date of Patent: May 26, 1998Assignee: Mitotix, Inc.Inventors: Jeno Gyuris, Lou Lamphere, Giulio Draetta
-
Patent number: 5744343Abstract: The present invention concerns three ubiquitin-conjugating enzymes.Type: GrantFiled: September 13, 1994Date of Patent: April 28, 1998Assignee: Mitotix, Inc.Inventors: Giulio Draetta, Mark Rolfe, Jens W. Eckstein, Guillaume Cottarel
-
Patent number: 5733920Abstract: The invention provides novel inhibitors of cyclin-dependent kinases, in particular inhibitors of the CDK/cyclin complexes such as CDK4/cyclin D1. The novel compounds are analogs of chromones. These compounds can be used for inhibiting excessive or abnormal cell proliferation. Thus, the novel compounds are useful for treating a subject with a disorder associated with excessive cell proliferation, such as cancer.Type: GrantFiled: October 31, 1995Date of Patent: March 31, 1998Assignee: Mitotix, Inc.Inventors: Muzammil M. Mansuri, Krishna K. Murthi, Kollol Pal
-
Patent number: 5691147Abstract: The present invention relates to the discovery of novel proteins of mammalian origin which can associate with the human cyclin dependent kinase 4 (CDK4).Type: GrantFiled: June 2, 1994Date of Patent: November 25, 1997Assignee: Mitotix, Inc.Inventors: Giulio Draetta, Jeno Gyuris
-
Patent number: 5672508Abstract: The present invention pertains to novel inhibitors of cyclin-dependent kinases (CDKs), particularly CDK/cyclin complexes, which inhibitors can be used to control proliferation and/or differentiation of cells in which the inhibitors are introduced. More specifically, the inhibitors of the invention are chimeric proteins which include CDK-binding motifs from two or more different proteins. For example, the subject chimeric proteins can be generated from the in-frame fusion of coding sequences from two different CDK inhibitor proteins, such as may be derived from fusion of coding sequences for an INK4 protein and coding sequences for a CIP protein. Chimeric proteins of the present invention have been observed to be more potent inhibitors of cyclin/CDK complexes than were either of the portions of the chimeric protein individually.Type: GrantFiled: January 23, 1996Date of Patent: September 30, 1997Assignee: Mitotix, Inc.Inventors: Jeno Gyuris, Lou Lamphere, David Beach
-
Patent number: 5443962Abstract: The present invention makes available assays and reagents for identifying anti-proliferative agents, such as mitotic and meiotic inhibitors, especially inhibitors of cdc25 phosphatase. The present assay provides a simple and rapid screening test which relies on scoring for positive cellular proliferation as indicative of anti-mitotic or anti-meiotic activity, and comprises contacting a candidate agent with a cell which has an impaired cell-cycle checkpoint and measuring the level of proliferation in the presence and absence of the agent. The checkpoint impairment is such that it either causes premature progression of the cell through at least a portion of a cell-cycle or inhibition of normal progression of the cell through at least a portion of a cell-cycle, but can be off-set by the action of an agent which inhibits at least one regulatory protein of the cell-cycle in a manner which counter-balances the effect of the impairment.Type: GrantFiled: June 4, 1993Date of Patent: August 22, 1995Assignee: Mitotix, Inc.Inventors: Giulio Draetta, Guillaume Cottarel, Veronique Damagnez